Free tool
FAERS Monitor: Rasuvo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205776 or its brand name (Rasuvo, Methotrexate). Reports on generic versions are filed under their own applications.
Reports
419,222
Serious
315,734
75% of reports
Hospitalization
119,931
Death reported
34,424
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective76,167
- rheumatoid arthritis38,742
- arthralgia37,040
- pain36,175
- off label use35,398
- fatigue29,748
- nausea24,560
- joint swelling22,754
- headache21,380
- rash20,425
- condition aggravated20,328
- drug intolerance20,034
- diarrhoea18,733
- pain in extremity18,205
- pyrexia17,500
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5,129 |
| 2005 | 5,083 |
| 2006 | 4,969 |
| 2007 | 7,782 |
| 2008 | 8,995 |
| 2009 | 9,160 |
| 2010 | 9,678 |
| 2011 | 10,610 |
| 2012 | 14,953 |
| 2013 | 16,975 |
| 2014 | 16,960 |
| 2015 | 20,367 |
| 2016 | 21,911 |
| 2017 | 22,794 |
| 2018 | 32,709 |
| 2019 | 32,625 |
| 2020 | 39,943 |
| 2021 | 26,674 |
| 2022 | 29,451 |
| 2023 | 27,028 |
| 2024 | 23,322 |
| 2025 | 20,237 |
| 2026 | 11,858 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,634,937 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 38,742 | 25.5 | 25.2 | 603,262 |
| drug intoleranceSignal | 20,034 | 12.9 | 12.7 | 174,560 |
| joint swellingSignal | 22,754 | 11.4 | 11.3 | 176,592 |
| arthralgiaSignal | 37,040 | 4.8 | 4.8 | 103,833 |
| condition aggravatedSignal | 20,328 | 3.5 | 3.5 | 34,777 |
| pain in extremitySignal | 18,205 | 3.2 | 3.2 | 26,795 |
| painSignal | 36,175 | 3.1 | 3.0 | 49,161 |
| drug ineffectiveSignal | 76,167 | 3.0 | 3.0 | 103,174 |
| pyrexiaSignal | 17,500 | 2.6 | 2.6 | 16,910 |
| rashSignal | 20,425 | 2.4 | 2.4 | 16,518 |
| off label useSignal | 35,398 | 2.1 | 2.1 | 19,643 |
| fatigue | 29,748 | 2.0 | 1.9 | 13,825 |
| headache | 21,380 | 1.7 | 1.7 | 6,641 |
| nausea | 24,560 | 1.6 | 1.6 | 5,186 |
| diarrhoea | 18,733 | 1.5 | 1.4 | 2,816 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.